Compare Stocks

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

Rio Silver Inc. engages in the acquisition, evaluation, and development of mineral properties in the Americas, Canada, and Peru. It explores for precious and base metal deposits. The company owns 100% interest in Niñobamba silver and gold project covering an area of 4,490 hectares located in the Department of Ayacucho, Peru. It also holds 100% interest in the Gerow Lake property, a base metal project located in northwestern Ontario, Canada; and holds 100% interest in Palpa Dorado property covering an area of 1,200 hectares located in Moro district of Santa province, Ancash, Peru. The company was formerly known as Escape Gold Inc. and changed its name to Rio Silver Inc. in October 2011. Rio Silver Inc. is based in Vancouver, Canada.

ProShares UltraShort Russell MidCap Value (the Fund) seeks daily investment results that correspond to twice the inverse daily performance of the Russell MidCap Value Index. The Russell MidCap Value Index measures the performance of the mid-capitalization value sector of the United States equity market. The Index represents approximately 52% of the total market capitalization of the Russell Midcap Index. The Index is a capitalization-weighted index and consists of those companies with lower price-to-book ratios within the Russell Midcap Index. The Fund intends to invest at least 80% of its net assets, including any borrowings for investment purposes, to investments that, in combination, have economic characteristics that are inverse to those of the Index. The Fund intends to concentrate its investments in a particular industry or group of industries to approximately the same extent as the Index is so concentrated. ProShare Advisors LLC serves as the investment advisor to the Fund.

Sunvest Minerals Corp. explores for and develops mineral properties in Canada and the United States. The company focuses on the Clone Gold project comprising 10,688 hectares situated in British Columbia. The company was formerly known as Strike Diamond Corp. and changed its name to Sunvest Minerals Corp. in March 2016. Sunvest Minerals Corp. was incorporated in 2008 and is based in Vancouver, Canada.